- Trial phase
- Phase 2 (RP completed); Phase 3 (PVRL on hold)
- Time to market
- Uncertain. The PVRL program is in regulatory limbo after the SPA withdrawal and IND transfer request. The RP program has Fast Track designation but no Phase 2/3 trial has been confirmed as initiated. Even under optimistic scenarios, any potential approval is likely several years away.
- Why 3/10
- ADX-2191 has no scheduled hard, dated catalyst (no PDUFA, no pivotal readout) in the next ~12 months. The November 9, 2026 IND transfer request and SPA withdrawal are regulatory process steps without a fixed decision date. The Phase 2 RP trial is already completed, and the planned Phase 2/3 RP trial has not been confirmed as initiated. The drug is a meaningful program for Aldeyra but the company also has the reproxalap program, and the stock's low valuation reflects multiple setbacks.
Watch for the FDA's decision on Aldeyra's jurisdiction transfer request for ADX-2191's IND, which will determine which division oversees the PVRL program and what development path will be required. Also monitor whether the planned Phase 2/3 trial in retinitis pigmentosa ever initiates, as that would provide a future catalyst. The company's cash runway and the reproxalap appeal outcome are broader factors affecting ALDX's ability to fund ADX-2191 development.
Price Chart
Executive Summary
ADX-2191 is Aldeyra Therapeutics' intravitreal (in-eye) formulation of methotrexate, developed for rare retinal diseases. The drug suffered a major setback in June 2023 when the FDA issued a Complete Response Letter for primary vitreoretinal lymphoma (PVRL), citing insufficient efficacy evidence. Although the FDA granted a Special Protocol Assessment in June 2025 for a new PVRL trial, Aldeyra unexpectedly withdrew that agreement on November 9, 2026, and requested transfer of the program to a different FDA division, putting the PVRL development path in limbo. Separately, ADX-2191 showed positive Phase 2 results in retinitis pigmentosa (RP) in June 2023 and received FDA Fast Track designation for RP in August 2025, but the planned Phase 2/3 RP trial does not appear to have started. With no upcoming binary catalyst and the PVRL program facing regulatory uncertainty, the near-term outlook for ADX-2191 is challenging.
How It Works
ADX-2191 is a formulation of methotrexate, a well-known anti-cancer and anti-inflammatory drug, that is injected directly into the vitreous humor (the gel-like fluid inside the eye). By delivering methotrexate locally to the eye, it aims to reduce inflammation and abnormal cell growth that cause vision loss in retinal diseases.
Trial Status
A Phase 2 trial in retinitis pigmentosa (NCT05392179, 8 patients) completed in June 2023 with positive top-line results showing improvement from baseline in retinal function. A Phase 3 trial in PVRL was planned under an FDA Special Protocol Assessment agreement (June 2025), but on November 9, 2026, Aldeyra withdrew the SPA and requested transfer of the IND to a different FDA division, putting the trial on hold. A Phase 2/3 trial in retinitis pigmentosa was planned for 2025 but does not appear to have initiated as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA decision on Aldeyra's request to transfer ADX-2191 IND from Division of Ophthalmology to Division of Hematologic Malignancies 2 (no set date)
- Potential initiation of Phase 2/3 trial in retinitis pigmentosa (if funded and initiated)
- FDA feedback on revised development path for PVRL following SPA withdrawal
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Aldeyra Therapeutics, Inc. 8-K ALDX ·Originating report